证券代码：002990 证券简称：盛视科技 公告编号：2025-087 盛视科技股份有限公司 本议案已经公司董事会战略委员会审议通过。 《关于投资设立全资子公司的自愿性信息披露公告》（公告编号：2025-088） 具 体 内 容 详 见 2025 年 8 月 22 日 《 证 券 时 报 》 及 巨 潮 资 讯 网 （http://www.cninfo.com.cn）。 三、备查文件 （一）公司第三届董事会第三十一次会议决议 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 盛视科技股份有限公司（以下简称"公司"）第三届董事会第三十一次会议 于 2025 年 8 月 21 日在公司会议室通过现场与通讯相结合的方式召开。本次董事 会会议通知于 2025 年 8 月 18 日以电子邮件、直接送达等方式向各位董事发出。 本次会议应出席董事 7 名（含独立董事 3 名），实际出席董事 7 名，公司监事及 高级管理人员列席了会议。会议由公司董事长瞿磊先生主持，本次会议的召集和 召开程序符合《中华人民共和国公司法》等法律法规和《公司章程》的规定，合 ...

Buyback and Shareholder Actions - Sinopec plans to repurchase A-shares with a total fund of no less than RMB 5 billion and no more than RMB 10 billion, potentially reducing its registered capital [1] - Hengbang Mining intends to reduce its stake in the Hong Kong-listed company, WanGuo Gold, by up to 40 million shares, representing approximately 3.69% of WanGuo's total share capital [5] Product Approvals and Market Launches - Wantai Biological's nine-valent HPV vaccine has received the batch release certificate, marking its official market launch and enhancing the company's product lineup [1] - Changchun High-tech's subsidiary has received acceptance for the clinical trial application of GenSci143, a dual-specific antibody drug, which may provide new treatment options for certain tumors [7] Financial Performance - Hongxin Electronics reported a 15.01% increase in revenue to RMB 3.494 billion and a 9.85% rise in net profit to RMB 53.99 million for the first half of 2025 [2] - Sanwei Xinan experienced a net loss of RMB 29.39 million in the first half of 2025, despite a 15.19% increase in revenue to RMB 195 million [3] Corporate Developments - TianTan Bio received a commitment from its controlling shareholder to resolve new competition issues arising from a recent acquisition [4] - Feilu Co. announced a potential change in control, leading to a temporary suspension of its stock trading [8] Investment and Expansion - Jinbei Electric's subsidiary has signed a purchase agreement for a factory in Europe, marking significant progress in establishing its European production base [1] - Shengshi Technology plans to establish a wholly-owned subsidiary to integrate AI and humanoid robot technology with innovative toy products, investing RMB 10 million [6]

Company Announcements - Dameng Data's board member and senior vice president is under investigation by the Hubei Provincial Supervisory Committee, but the company's operations remain normal [1] - Jishi Media reported a net loss of 232 million yuan in the first half of 2025, despite a revenue increase of 8.7% to 999.7 million yuan [2] - Wantai Biological's nine-valent HPV vaccine has received its first batch release certificate, marking its market entry and potential revenue growth [2] - Feilu Co., Ltd. is undergoing a change in control, leading to a suspension of its stock trading starting August 22 [2] Financial Performance - Sany Heavy Industry reported a 46% increase in net profit to 5.216 billion yuan in the first half of 2025, with a revenue of 44.534 billion yuan, up 14.96% [3] - EVE Energy's net profit decreased by 24.9% to 1.605 billion yuan, despite a revenue increase of 30.06% to 28.169 billion yuan [5] - GoerTek achieved a net profit increase of 15.65% to 1.42 billion yuan, with a revenue of 37.55 billion yuan, down 7.02% [6] Approvals and Projects - Changchun High-tech's subsidiary received acceptance for a clinical trial application for GenSci143, a dual-specificity antibody drug targeting B7-H3 and PSMA [7] - Zejing Pharmaceutical received approval for clinical trials of ZG005 and ZGGS18 in combination with a specific cancer drug [7] Financing and Capital Increase - Zhenghe Industrial plans to raise no more than 818 million yuan through a private placement for various projects and working capital [8] Shareholding Changes - Zhongyin Securities announced that Jiangxi Copper plans to reduce its stake by up to 3%, equating to 83.34 million shares [9] - Mengke Pharmaceutical's shareholders plan to transfer 22.946 million shares, representing 3.5% of the total share capital [15] Investments and Strategic Partnerships - Diou Home plans to establish a wholly-owned subsidiary with an investment of 500 million yuan to expand into the generative AI field [11] - Gree Green signed a strategic cooperation agreement with Weilan Lithium to develop ultra-high energy density battery materials and solid-state battery innovations [12]

2024年1至12月份，盛视科技的营业收入构成为：软件与信息技术服务占比99.51%，其他业务占比 0.49%。 （文章来源：每日经济新闻） 盛视科技（SZ 002990，收盘价：32.27元）8月21日晚间发布公告称，公司第三届第三十一次董事会会 议于2025年8月21日在公司会议室通过现场与通讯相结合的方式召开。会议审议了《关于投资设立全资 子公司的议案》等文件。 ...

（文章来源：每日经济新闻） 盛视科技（SZ 002990，收盘价：32.27元）8月21日晚间发布公告称，盛视科技股份有限公司于2025年8 月21日召开第三届董事会第三十一次会议，审议通过了《关于投资设立全资子公司的议案》。根据业务 发展和实际经营需要，公司拟使用自有资金以现金出资方式，投资设立全资子公司深圳菲菲特文化创新 有限公司，该子公司注册资本为人民币1000万元，公司持有其100%股权。 2024年1至12月份，盛视科技的营业收入构成为：软件与信息技术服务占比99.51%，其他业务占比 0.49%。 ...

Group 1: Company Performance - Sinopec reported a revenue of 1.4 trillion yuan and a net profit of 23.75 billion yuan for the first half of 2025, with a cash dividend of 0.088 yuan per share, representing a payout ratio of 49.7% [1] - GoerTek achieved a net profit of 1.42 billion yuan, marking a year-on-year increase of 15.65%, despite a revenue decline of 7.02% to 37.55 billion yuan [2] - Gree Electric announced a cash dividend of 20 yuan per 10 shares, totaling 11.17 billion yuan, based on a share base of 5.585 billion shares [3] - Jishi Media reported a revenue of 999.7 million yuan, with a net loss of 232 million yuan for the first half of 2025 [4] - Changchun High-tech's subsidiary received approval for a clinical trial of a dual-specific antibody drug, GenSci143, targeting B7-H3 and PSMA [5] - Greenme announced a strategic partnership with Weilan Lithium to develop high-energy battery materials and solid-state battery technologies [6] Group 2: Share Buybacks and Reductions - Sinopec plans to repurchase shares worth between 5 billion and 10 billion yuan through the Shanghai Stock Exchange [26] - Jiangxi Copper intends to reduce its stake in Zhongyin Securities by up to 3%, equating to 83.34 million shares [7] - Hengbang Mining plans to reduce its stake in the Hong Kong-listed company, WanGuo Gold, by up to 3.69% of its total share capital [10] Group 3: New Product Developments - Renhe Pharmaceutical's subsidiary is developing a brain-machine interaction smart glasses product, which is currently in the testing phase and has not yet generated sales revenue [11] - TianTan Bio received a commitment from its controlling shareholders to resolve new competition issues arising from a recent acquisition [12] - XianDao Intelligent has successfully developed a mass production solution for solid-state batteries and received repeat orders for related products [13] - Zejing Pharmaceutical received approval for clinical trials of ZG005 and ZGGS18 in combination with a cancer treatment drug [14] - Wantai Bio received a production approval for its nine-valent HPV vaccine, marking a new revenue stream [15]

格隆汇8月21日丨盛视科技(002990.SZ)公布，公司于2025年8月21日召开第三届董事会第三十一次会 议，审议通过了《关于投资设立全资子公司的议案》。根据业务发展和实际经营需要，公司拟使用自有 资金以现金出资方式，投资设立全资子公司深圳菲菲特文化创新有限公司(暂定名，具体以当地登记机 关核准为准)，该子公司注册资本为人民币1,000万元，公司持有其100%股权。 ...

盛视科技股份有限公司 证券代码：002990 证券简称：盛视科技 公告编号：2025-088 关于投资设立全资子公司的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 盛视科技股份有限公司（以下简称"公司"、"盛视科技"）于 2025 年 8 月 21 日召开第三届董事会第三十一次会议，审议通过了《关于投资设立全资子 公司的议案》。根据业务发展和实际经营需要，公司拟使用自有资金以现金出资 方式，投资设立全资子公司深圳菲菲特文化创新有限公司（暂定名，具体以当地 登记机关核准为准），该子公司注册资本为人民币 1,000 万元，公司持有其 100% 股权。 根据《深圳证券交易所股票上市规则》及《公司章程》等有关规定，本次投 资在董事会审议权限内，无需提交股东大会审议。董事会授权公司管理层及相关 人员办理工商核准登记有关事宜。 本次投资不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。 二、投资标的基本情况 1.公司名称（暂定）：深圳菲菲特文化创新有限公司 2.公司类型：有限责任公司 以上信息最终以当地登 ...

证券代码：002990 证券简称：盛视科技 公告编号：2025-087 盛视科技股份有限公司 第三届董事会第三十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 盛视科技股份有限公司（以下简称"公司"）第三届董事会第三十一次会议 于 2025 年 8 月 21 日在公司会议室通过现场与通讯相结合的方式召开。本次董事 会会议通知于 2025 年 8 月 18 日以电子邮件、直接送达等方式向各位董事发出。 本次会议应出席董事 7 名（含独立董事 3 名），实际出席董事 7 名，公司监事及 高级管理人员列席了会议。会议由公司董事长瞿磊先生主持，本次会议的召集和 召开程序符合《中华人民共和国公司法》等法律法规和《公司章程》的规定，合 法有效。 二、董事会会议审议情况 审议通过《关于投资设立全资子公司的议案》 根据业务发展和实际经营需要，公司拟使用自有资金以现金出资方式，投资 设立全资子公司深圳菲菲特文化创新有限公司（暂定名，具体以当地登记机关核 准为准），该子公司注册资本为人民币 1,000 万元，公司持有其 100%股权。授 ...

盛视科技公告，公司于2025年8月21日召开第三届董事会第三十一次会议，审议通过了《关于投资设立 全资子公司的议案》。公司拟使用自有资金以现金出资方式，投资设立全资子公司深圳菲菲特文化创新 有限公司（暂定名），注册资本为人民币1000万元，公司持有其100%股权。此次投资不构成关联交 易，亦不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 ...